New Products: MLL's AML/MDS Panel; Adaptive Biotechnologies' ClonoSeq | GenomeWeb

Munich Leukemia Laboratory has developed a 31-gene sequencing panel to identify markers to sub-classify acute myeloid leukemia and myelodysplastic syndromes using RainDance enrichment technology and 2x250 base pair sequencing on the Illumina MiSeq.


Adaptive Biotechnologies has launched ClonoSeq, a next-generation sequencing-based assay to detect minimal residual disease in blood-based cancers. The assay will be available for widespread use by mid-2013, according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.